Recent Updates
Recently added Catalysts
ERAS Positive Sentiment Score: 75/100

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

Wednesday, May 31, 2023 2 min read
Key Takeaway: Erasca, Inc. has announced a virtual investor event scheduled for June 5, 2023, where the leadership team will provide updates on their pipeline, specifically highlighting ERAS-007, an ERK1/2 inhibitor in clinical development. This event aims to engage investors and share advancements in targeted therapies for RAS/MAPK pathway-driven cancers. The company's strategy focuses on innovative cancer treatments, leveraging expert insights in the field. A live Q&A session will follow the presentation, allowing direct interaction with the leadership team.

Market Sentiment Analysis

POSITIVE FACTORS

  • Erasca is hosting a virtual investor event which shows engagement with investors.
  • The focus on the promising ERAS-007 ERK inhibitor suggests potential breakthroughs in cancer treatment.
  • The company emphasizes its commitment to developing novel therapies for RAS/MAPK pathway-driven cancers.
  • Erasca's leadership includes pioneers in precision oncology, enhancing its credibility and potential.

Full Press Release Details

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it will host a virtual investor event on Erasca pipeline updates on Monday, June 5, 2023, at 4:30 PM ET.
The Erasca leadership team will discuss its pipeline targeting RAS/MAPK pathway-driven cancers, with a focus on ERAS-007, a potentially best-in-class ERK1/2 inhibitor in Phase 1b/2 clinical development for the treatment of patients with RAS/MAPK pathway-altered solid tumors.
A live question and answer session will follow the formal presentation. To register for the event, please click here.
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.

Frequently Asked Questions

What is Erasca, Inc. focused on?

Erasca, Inc. targets therapies for RAS/MAPK pathway-driven cancers.

When is the virtual investor event hosted by Erasca?

The event is on June 5, 2023, at 4:30 PM ET.

What is ERAS-007?

ERAS-007 is a Phase 1b/2 ERK1/2 inhibitor for solid tumors.

Who founded Erasca?

Erasca was co-founded by pioneers in precision oncology.

What is Erasca's mission?

Erasca's mission is to erase cancer through innovative therapies.

Tags: ERAS Viatris Investor Conferences Healthcare Erasca oncology ERK inhibitor clinical development
Last updated: May 31, 2023